Conference Call with Gland Pharma Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Gland Pharma announced Q1FY26 results Revenue increased to 15,056 million from Rs 14,017 million during Q1FY25, change 7% YoY and by 6% QoQ. EBITDA increased by 39% YoY and by 6% QoQ. EBITDA margin increased by 549 bps YoY to 24% in Q1FY26. Adj. EBITDA increased by 41% YoY and by 8% QoQ. Adj. EBITDA margin increased by 589 bps YoY to 25% in Q1FY26. PAT increased to Rs 2,155 million from Rs 1,438 million during Q1FY25, change 50% YoY and by 16% QoQ. PAT margin increased by 405 bps YoY to 14% in Q1FY26. Srinivas Sadu, Executive Chairman, Gland Pharma, said: “We're off to a positive start this year with a growth in revenue and a significant jump in profitability, which was driven by a strong performance in our base business and a turnaround at Cenexi. These results show our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D; with complex products and key partnerships. We're committed to building on this strong foundation, improving our performance, and reinforcing Gland's path toward sustainable growth” Shyamakant Giri, Chief Executive Officer, Gland Pharma, said: “This quarter’s performance, with improved margins and Cenexi achieving EBITDA break even, reinforces the progress we are making in delivering our long-term vision. By enhancing our base business, investing in differentiated products, and driving operational efficiencies, we are positioning ourselves for sustained growth. At the same time, our continued focus on R&D;, adherence to global quality standards, and investment in capability building position us to scale further, tap new markets, and deliver long-term value.” Result PDF